Last week, Insilico Medicine announced the start of Phase III trials for rentosertib, an oral TNIK inhibitor for idiopathic pulmonary fibrosis (IPF). At first glance, the news seems like just another biotechnology milestone among many. But it's unlike anything we've seen so far, and it's worth understanding why before we return to the discussion about the Brazilian program for radical innovation in healthcare. Rentosertib is the first molecule in history to reach a pivotal Ph

In June 2025, the US Food and Drug Administration approved a new HIV pre-exposure prophylaxis (PrEP) regimen: the long-acting injectable...

The emergence of cutting-edge technologies, known as deeptechs, marks a new phase in global innovation. These technologies, which emerge...

Technological innovation is a fundamental factor for a country’s economic development and competitiveness. In Brazil, intellectual...

Brazil’s biodiversity, widely recognized as one of the richest in the world, offers a window of opportunity for innovative health...

Health innovation and the remarkable growth of the pharmaceutical sector—with a projected global revenue of USD 1.155 trillion in...